Prenatal exposure to valproic acid during pregnancy and limb deficiencies: A case-control study

American Journal of Medical Genetics

Volumn 90, Issue 5, 2000, Pages 376-381

  Rodríguez Pinilla, Elvira ^a   Arroyo, Ignacio ^b   Fondevilla, Juan ^c   García, Maria José ^d   Martínez Frías, Maria Luisa ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b Servicio de Microbiología Clínica Hospital S Pedro de Alcántara   (Spain)

^c HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

^d HOSPITAL VIRGEN DE LA LUZ   (Spain)

Author keywords

Congenital malformations; Limb deficiencies; Valproic acid

Indexed keywords

VALPROIC ACID;

ARACHNODACTYLY; ARTICLE; CLINICAL FEATURE; CLINODACTYLY; CLUBFOOT; CONTROLLED STUDY; HIP DISLOCATION; HUMAN; INFANT; LIMB DEFECT; MAJOR CLINICAL STUDY; NEWBORN; PES EQUINOVARUS; POLYDACTYLY; PREGNANCY; PRENATAL EXPOSURE; PRIORITY JOURNAL;

ANTICONVULSANTS; CASE-CONTROL STUDIES; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LIMB DEFORMITIES, CONGENITAL; LOGISTIC MODELS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; VALPROIC ACID;

EID: 0342680127     PISSN: 01487299     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8628(20000228)90:5<376::AID-AJMG6>3.0.CO;2-V     Document Type: Article

References (29)

1. Ardinger HH, Atkin JF, Blackston RD, Elsas LJ, Clarren SK, Livingstone S, Flannery DV, Pellock JM, Harrod MJ, Lammer EJ, Majewski F, Schinzel A, Toriello HV, Hanson JW. 1988. Verification of the fetal valproate syndrome phenotype. Am J Med Genet 29:171-185.
2. ATC Classification. 1990. Guidelines for ATC classification (1990) WHO Collaborating Centre for Drug Statistic Methodology, Norway and Nordic Council on Medicines, Sweden.
3. Bailey CJ, Pool RW, Poskitt EME, Harris F. 1983. Valproic acid and fetal abnormality. Lancet 1:190.
4. Bermejo-Sánchez E, Martínez-Frías ML. 1997. Vigilancia epidemiológica de las malformaciones congénitas. Boletín del ECEMC: Revista de Dismorfología y Epidemiología 4:43-114.
5. Bjerkedal TA, Czeizel A, Goujard J, Källén B, Mastroiacovo P, Nevin N, Oakley G Jr, Robert E. 1982. Valproic acid and spina bifida. Lancet 2:1096.
6. Brons JT, van der Harten HJ, van Geijn HP, Wladimiroff JW, Niermeijer MF, Lindhout D, Stuart PA, Meijer CJ, Arts NF. 1990. Prenatal ultrasonographic diagnosis of radial-ray reduction malformations. Prenat Diagn 10:279-288.
7. Carter BS, Stewart JM. 1988. Valproic acid prenatal exposure. Association with lipomyelomeningocele. Clin Pediatr 28:81-85.
8. Clayton-Smith J, Donnai D. 1995. Fetal valproate syndrome. J Med Genet 32:724-727.
9. DiLiberti JH, Farndon PA, Dennis NR, Curry CJR. 1984. The fetal valproate syndrome. Am J Med Genet 19:473-481.
10. Graham JM Jr, Sharony R, Garber A, Schreck R, Platt LD, Buehler BA. 1991. Preaxial ray reduction defects valproate exposure during pregnancy. Teratology 43:441.
11. Hendrickx AG, Nau H, Binkerd P, Rowland JM, Rowland JR, Cukierski MJ, Cukierski MA. 1988. Valproic acid developmental toxicity and pharmacokinetics in rhesus monkey: an interspecies comparison. Teratology 38:329-345.
12. Jager-Roman E, Deichl A, Jakob S, Hartmann AM, Koch S, Rating D, Steldinger R, Nau H, Helge H. 1986. Fetal growth, major malformations, and minor anomalies in infants born to woman receiving valproic acid. J Pediatr 108:997-1004.
13. Khoury MJ. 1995. Commentary: Contributions of epidemiology to the study of birth defects in humans. Teratology 52:186-189.
14. Lammer EJ, Sever LE, Oakley GP Jr. 1987. Teratogen update: valproic acid. Teratology 35:465-473.
15. Langer B, Haddad J, Gasser B, Maubert M, Schlaeder G. 1994. Isolated fetal bilateral ray reduction associated with valproic acid usage. Fetal Diagn Ther 9:155-158.
16. Lindhout D, Meinardi H. 1984. Spina bifida and in-utero exposure to valproate. Lancet 2:396.
17. Martínez-Frías ML, Rodríguez-Pinilla E, Salvador J. 1989. Valproate and spina bifida. Lancet 1:611.
18. Martínez-Frías ML. 1990. Clinical manifestation of prenatal exposure to valproic acid using case reports and epidemiologic information. Am J Med Genet 37:277-282.
19. Martínez-Frías ML, Rodríguez-Pinilla E, Prieto L. 1997. Prenatal exposure to salicylates and gastroschisis: a case-control study. Teratology 56: 241-243.
20. Martínez-Frias, ML, Rodríguez-Pinilla E, Bermejo E, Prieto L. 1988. Prenatal exposure to sex hormones: a case-control study. Teratology 57:8-12.
21. Mastroiacovo P, Bertollini R, Morandini S, Segni G. 1983. Maternal epilepsy, valproate exposure, and birth defects. Lancet 2:1499.
22. Okada T, Tomoda T, Hisakawa H, Kurashige T. 1995. Fetal valproate syndrome with reduction deformity of limb. Acta Paediatr Jpn 37:58-60.
23. Paulson RB, Sucheston ME, Hayes TG, Paulson GW. 1985. Teratogenic effects of valproate in the CD-1 mouse fetus. Arch Neurol 42:980-983.
24. Prieto L, Martínez-Frías ML. 1999. Case-control studies using only malformed infants: are we interpreting the results correctly? Teratology 60:1-2.
25. Robert E, Guibaud P. 1982. Maternal valproic acid and congenital neural tube defects. Lancet 2:937.
26. Robert E, Rosa F. 1983. Valproate and birth defects. Lancet 2:1142.
27. Sharony R, Garber A, Viskochil D, Schreck R, Platt LD, Buehler BA, Graham JM Jr. 1993. Preaxial ray reduction defects as part of valproic acid embryofetopathy. Prenat Diagn 13:909-918.
28. Verloes A, Frikiche A, Gremillet C, Paquay T, Decortis T, Rigo J, Senterre J. 1990. Proximal phocomelia and radial ray aplasia in fetal valproic syndrome. Eur J Pediatr 149:266-267.
29. Winter RM, Donnai D, Burn J, Tucker SM. 1987. Fetal valproate syndrome: Is there a recognisable phenotype? J Med Genet 24:692-695.